Merit Medical Systems (MMSI) has drawn fresh attention after recent share price moves, with the stock up 0.8% on the day but lower over the past month and the past 3 months.

The recent 7 day share price return of 4.58% contrasts with weaker 30 day and 90 day share price performance. In addition, the 1 year total shareholder return of a 32.72% decline suggests momentum has been fading rather than building.

If you are considering other opportunities in healthcare-related technologies, this could be a good moment to see what else is moving and check out 34 healthcare AI stocks.

So with Merit Medical Systems down over the past year but trading at a discount to some analyst and intrinsic estimates, is this a genuine value opportunity for patient investors, or is the market already pricing in future growth?

Most Popular Narrative: 34.8% Undervalued

With Merit Medical Systems last closing at $64.17 against a narrative fair value of $98.36, the current price sits well below that benchmark while analysts debate how much of the story is already in the price.

The expanding global prevalence of chronic diseases and an aging population are increasing the need for interventional, diagnostic, and therapeutic medical procedures. Merit's strong growth in cardiovascular and endoscopy segments, robust new product development, and recent acquisitions (such as Biolife and EndoGastric) position the company to capture a larger share of this growing market and drive sustained long-term revenue growth.

Want to see how that growth story turns into a nearly one third gap to the share price? The narrative leans on steady revenue expansion, higher margins, and a richer future earnings multiple, all brought back to today using a single discount rate and a detailed earnings path that might surprise you.

Result: Fair Value of $98.36 (UNDERVALUED)

However, that story can quickly change if WRAPSODY CIE reimbursement setbacks persist, or if tariffs and trade tensions lift costs and pressure margins more than expected.

Another way to look at valuation

On earnings multiples, Merit Medical Systems looks less clear cut. The stock trades on a P/E of 27.5x, which is higher than the US Medical Equipment industry average of 24.5x, and above its own fair ratio of 21.9x. This suggests some valuation risk if sentiment cools.

For a closer read on what those P/E gaps could mean for future pricing power and downside risk, check the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Curious whether this cautious tone matches your own view of Merit Medical Systems? Move quickly, review the positives for yourself, and weigh up the 3 key rewards

Looking for more investment ideas?

You have already done the hard work by understanding Merit Medical Systems, so do not stop here when there are other opportunities worth putting on your radar.

• Target quality at a discount by scanning for solid businesses trading below their estimated value through the 48 high quality undervalued stocks.
• Strengthen your income potential by reviewing companies that feature reliable payouts in the 10 dividend fortresses.
• Stay one step ahead by spotting future standouts early using the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.